Last reviewed · How we verify

Standard Dose Colistin — Competitive Intelligence Brief

Standard Dose Colistin (Standard Dose Colistin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polymyxin antibiotic. Area: Infectious Disease.

marketed Polymyxin antibiotic Bacterial lipopolysaccharides and phospholipids Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Standard Dose Colistin (Standard Dose Colistin) — King Saud Medical City. Colistin disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, causing cell lysis and death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Standard Dose Colistin TARGET Standard Dose Colistin King Saud Medical City marketed Polymyxin antibiotic Bacterial lipopolysaccharides and phospholipids
Polymyxin e Polymyxin e Mahmoud I Mostafa marketed Polymyxin antibiotic Bacterial lipopolysaccharides and phospholipids
Coly Mycin M Injectable Product Coly Mycin M Injectable Product Chia Tai Tianqing Pharmaceutical Group Co., Ltd. phase 3 Polymyxin antibiotic Bacterial lipopolysaccharides and phospholipids
Colistin/Polymyxin B + Sulbactam Colistin/Polymyxin B + Sulbactam National University of Singapore marketed Polymyxin antibiotic + β-lactamase inhibitor combination Bacterial cell membrane (polymyxins); bacterial β-lactamases (sulbactam)
Ceftazidime-avibactam + Colistin/Polymyxin B Ceftazidime-avibactam + Colistin/Polymyxin B National University of Singapore marketed Beta-lactam/beta-lactamase inhibitor + polymyxin antibiotic combination Bacterial peptidoglycan cross-linking enzymes (PBPs); beta-lactamases; bacterial cell membrane lipopolysaccharide and phospholipids
High Dose Colistin High Dose Colistin King Saud Medical City marketed Polymyxin antibiotic Bacterial lipopolysaccharide (LPS) and outer membrane
Colistimethate sodium (CMS) Colistimethate sodium (CMS) Merck Sharp & Dohme LLC phase 3 Polymyxin antibiotic Bacterial lipopolysaccharide (LPS)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polymyxin antibiotic class)

  1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  2. King Saud Medical City · 2 drugs in this class
  3. Hospitales Universitarios Virgen del Rocío · 1 drug in this class
  4. Mahmoud I Mostafa · 1 drug in this class
  5. Merck Sharp & Dohme LLC · 1 drug in this class
  6. Vanderbilt University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard Dose Colistin — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-dose-colistin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: